Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
38 studies found for:    AD02 Alzheimer's
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Biological: AFFITOPE AD02
2 Completed Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: active: AFFITOPE AD02;   Biological: control: Placebo
3 Terminated Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
Condition: Alzheimer´s Disease
Interventions: Biological: AFFITOPE® AD02;   Biological: Placebo
4 Completed Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02
Condition: Alzheimer's Disease
Intervention: Biological: AFFITOPE AD02
5 Completed Long-term Safety and Tolerability of AFFITOPE AD02
Condition: Alzheimer's Disease
Intervention:
6 Terminated Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease
Condition: Alzheimer´s Disease
Intervention:
7 Completed Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Interventions: Biological: CAD106;   Drug: Placebo
8 Completed Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)
Condition: Alzheimer's Disease
Intervention:
9 Completed Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Condition: Alzheimer's Disease
Interventions: Drug: E2609;   Drug: Placebo for E2609
10 Completed Brain Imaging in Alzheimer's Disease
Condition: Alzheimer Disease
Intervention: Drug: [123] 5-I-A-85380
11 Completed Effect of LY2062430 on the Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430;   Drug: Placebo
12 Active, not recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 150 mg/day;   Drug: TRx0237 250 mg/day;   Drug: Placebo
13 Active, not recruiting MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
Condition: Alzheimer Disease
Interventions: Drug: RO4601522;   Drug: RO4602522;   Drug: donepezil;   Drug: galantamine;   Drug: memantine;   Drug: placebo;   Drug: rivastigmine
14 Completed
Has Results
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY450139;   Drug: Placebo
15 Completed Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II
Condition: Alzheimer Disease
Intervention:
16 Completed Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone Extended Release 2mg;   Drug: Rosiglitazone Extended Release 8mg;   Other: Placebo;   Other: Donepezil;   Other: Galantamine;   Other: Rivastigmine
17 Completed Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder
Conditions: Alzheimer Disease;   Dementia;   Memory Disorder;   Healthy
Intervention:
18 Completed Alzheimer's Family Research
Condition: Decision Making
Intervention:
19 Completed A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Drug: Placebo;   Drug: RO5313534
20 Terminated
Has Results
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Bapineuzumab 1.0 m/kg

   Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results    Last Page
Indicates status has not been verified in more than two years